Literature DB >> 499249

Semi-quantitative interpretation of the bone scan in metabolic bone disease: definition and validation of the metabolic index.

I Fogelman, D L Citrin, J G Turner, I D Hay, R G Bessent, I T Boyle.   

Abstract

Certain easily recognisable features are commonly seen in the bone scans of patients with metabolic bone disorders. Seven such features have been numerically graded by three independent observers in the scans of 100 patients with metabolic bone disease and of 50 control subjects. The total score for each patient is defined as the metabolic index. The mean metabolic index for each group of patients with metabolic bone disease is significantly greater than that for the control group (P less than 0.001).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 499249     DOI: 10.1007/bf00304886

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  6 in total

1.  Bone scan in chronic dialysis patients with evidence of secondary hyperparathyroidism and renal osteodystrophy.

Authors:  W M Sy; A K Mittal
Journal:  Br J Radiol       Date:  1975-11       Impact factor: 3.039

2.  Scintigraphic skeletal changes in uremic patients on regular hemodialysis.

Authors:  K Olgaard; J Heerfordt; S Madsen
Journal:  Nephron       Date:  1976       Impact factor: 2.847

3.  The role of bone scanning in osteomalacia.

Authors:  I Fogelman; J H McKillop; R G Bessent; I T Boyle; J G Turner; W R Greig
Journal:  J Nucl Med       Date:  1978-03       Impact factor: 10.057

Review 4.  Bone trauma and related benign disease: assessment by bone scanning.

Authors:  R Marty; J D Denney; M R McKamey; M J Rowley
Journal:  Semin Nucl Med       Date:  1976-01       Impact factor: 4.446

5.  Technetium-99m-Sn-pyrophosphate pharmaco-kinetics and bone image changes in parathyroid disease.

Authors:  G T Krishnamurthy; A S Brickman; W H Blahd
Journal:  J Nucl Med       Date:  1977-03       Impact factor: 10.057

6.  The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease.

Authors:  I Fogelman; R G Bessent; J G Turner; D L Citrin; I T Boyle; W R Greig
Journal:  J Nucl Med       Date:  1978-03       Impact factor: 10.057

  6 in total
  8 in total

1.  High bone turnover in fibromyalgia.

Authors:  T Appelboom; A Schoutens
Journal:  Calcif Tissue Int       Date:  1990-05       Impact factor: 4.333

Review 2.  Bone scintigraphy in benign bone disease.

Authors:  J H McKillop; I Fogelman
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28

3.  Total parathyroidectomy and parathyroid autograft for renal osteodystrophy: analysis of the cause of failure.

Authors:  P Kinnaert; J L Vanherweghem; M Fuss; A Schoutens; P Bergmann; M Dratwa; J van Geertruyden
Journal:  World J Surg       Date:  1985-06       Impact factor: 3.352

4.  Differential diagnosis between secondary hyperparathyroidism and aluminum intoxication in uremic patients: usefulness of 99mTc-pyrophosphate bone scintigraphy.

Authors:  P Kinnaert; I Van Hooff; A Schoutens; P Bergmann; M Fuss; M Dratwa; A Vienne; J L Pasteels; J van Geertruyden; J L Vanherweghem
Journal:  World J Surg       Date:  1989 Mar-Apr       Impact factor: 3.352

5.  The value of bone scintigraphy in the follow-up of vertebral osteoporosis.

Authors:  H Rico; E Merono; J Del Olmo; M Revilla
Journal:  Clin Rheumatol       Date:  1991-09       Impact factor: 2.980

6.  Diphosphonates in the evaluation of metabolic bone disease.

Authors:  I Fogelman; M L Smith
Journal:  Clin Rheumatol       Date:  1982-03       Impact factor: 2.980

7.  Bone scintigraphy and densitometry in symptomatic haemodialysis bone disease.

Authors:  C Alberts; J B van der Schoot; E Busemann-Sokole
Journal:  Eur J Nucl Med       Date:  1981

Review 8.  Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure.

Authors:  F A de Jonge; E K Pauwels; N A Hamdy
Journal:  Eur J Nucl Med       Date:  1991
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.